Trials / Completed
CompletedNCT02109250
CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this registry it is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa® (vandetanib). The characteristics of patients receiving Caprelsa® (vandetanib) will be described. Therefore real life data regarding demographic characteristics, evolution of the disease, RET mutation status, the treatment before, during and after vandetanib, dose and duration of treatment with Caprelsa® (vandetanib) and time of progression or death (if applicable) will be included.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Caprelsa | Caprelsa® 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib. |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2014-04-09
- Last updated
- 2017-05-02
Locations
8 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02109250. Inclusion in this directory is not an endorsement.